Please login to the form below

Not currently logged in
Email:
Password:

trebananib

This page shows the latest trebananib news and features for those working in and with pharma, biotech and healthcare.

Takeda hands back rights to two Amgen drugs

Takeda hands back rights to two Amgen drugs

However, Takeda has decided it is no longer interested in developing pain candidate fulranumab (AMG403) and trebananib (AMG386), which is being tested in cancer. ... In the case of trebananib the picture seems clearer - the compound has already failed

Latest news

  • Amgen's trebananib misses survival target in ovarian cancer Amgen's trebananib misses survival target in ovarian cancer

    tumours. In the phase III study - called TRINOVA-1 - trebananib plus paclitaxel was compared to paclitaxel alone in women with recurrent platinum-resistant ovarian cancer. ... he described the overall survival data from TRINOVA-1 as a "binary event" for

  • Late-stage ovarian cancer Late-stage ovarian cancer

    Trebananib appears to be closer than nintedanib to approval, given that the primary endpoint (PFS) was achieved in the phase III TRINOVA-1 trial. ... In this trial, 919 patients with recurrent ovarian, primary peritoneal or fallopian tube cancers were

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics